DUBLIN--(BUSINESS WIRE)--The "Western Blotting: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for Western blotting was valued at $1.4 billion in 2022 ...

Bio-Rad Laboratories, Inc. (BIO) has experienced a rise in revenue growth in recent years thanks to strong sales of its Western Blotting, Digital PCR, and Process Media life science products. Several ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today released the first set in a new product line of PrecisonAb™ Antibodies, rigorously validated for use in western blotting. These antibodies offer ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for ...

Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to the Bio-Rad Third Quarter 2023 Financial Results Conference Call and Webcast. [Operator Instructions] And please be advised ...

Bio-Rad Laboratories stock (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 48% fall this year, significantly underperforming the broader S&P500 index, down 24 ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its isotype-specific secondary antibodies.

Bio-Rad Laboratories, Inc. BIO is set to release second-quarter 2023 results on Aug 3 after the closing bell. The company posted adjusted earnings per share (EPS) of $3.34 in the last reported quarter ...